Icaritin inhibits lung cancer-induced osteoclastogenesis by suppressing the expression of IL-6 and TNF-a and through AMPK/mTOR signaling pathway

Abstract

Bone metastasis is one of the common phenomena in the late stage of lung cancer. Inhibition of bone metastasis can improve the survival of lung cancer patients. However, the current drugs for the treatment of bone metastasis have shown little effect on overall survival. Therefore, there is an urgent necessity to identify novel drugs capable of preventing and treating bone metastasis of lung cancer. Our study determined that icaritin (ICT) can inhibit lung cancer-mediated osteoclastogenesis and induce the apoptosis of osteoclasts. Exposure to ICT increased the activation of adenosine 5’-monophosphate-activated protein kinase (AMPK), reduced the activation of mammalian target of rapamycin (mTOR) and decreased the expression of bcl-2. The bioactivity of ICT on osteoclastogenesis was associated with the regulation of the AMPK/mTOR signaling pathway. Blocking AMPK significantly increased osteoclast differentiation, decreased osteoclast apoptosis and canceled the effects of ICT on the phosphorylation of AMPK as well as the inhibition of mTOR and bcl-2. Furthermore, ICT decreased the levels of IL-6 and TNF-α in osteoclasts, while the AMPK inhibitor compound C significantly abolished the inhibitory effects of ICT on IL-6 and TNF-α. Thus, the present study demonstrated that ICT may be a potential natural agent for the treatment of bone metastasis in patients with lung cancer.

Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer

“…Icaritin is a hydrolysate of icariin, one of the main active components of Epimedium. In recent years, icaritin has been considered as a potential cancer suppressor because of its inhibitory effect on tumors such as lymphoma, lung cancer, and prostate cancer (Wu et al., 2015 , 2020 ; Zhao et al., 2020 ). Wu et al.…”

The Function of Metformin in Aging-Related Musculoskeletal Disorders

“…In addition, metformin can also down-regulate the levels of osteoclastogenesis-related signaling molecules. Activated AMPK can down-regulate C-fos, NFATc1 and NF-κB levels ( Oh et al, 2016 ; Salminen et al, 2019 ; Zhao et al, 2020 ). Both TNF-α and IL-6 (downstream of NF-κB) can positively regulate osteoclast differentiation and function ( Luo et al, 2018 ; Wang and He, 2020 ).…”

How zoledronic acid improves osteoporosis by acting on osteoclasts

“…A study has shown that AMP-activated protein kinase (AMPK) plays a negative regulatory role in osteoclast differentiation and function ( Tong et al, 2020 ). Multiple drugs can affect osteoclast differentiation and bone resorption through AMPK-mediated signaling pathways, such as AMPK/NF-κB/ERK, AMPK/mTOR/p70S6K, and AMPK/Nfr2 signaling pathways ( Li Z et al, 2018 ; Tong et al, 2018 ; Peng et al, 2019 ; Zhao et al, 2020 ; Guo et al, 2021 ). Unlike various other drugs whose effects on osteoclast differentiation and bone resorption through AMPK pathway have been widely studied, studies on how ZA affects osteoclasts through the AMPK pathway are relatively recent.…”